BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22866966)

  • 1. Statin drug interactions and related adverse reactions.
    Bellosta S; Corsini A
    Expert Opin Drug Saf; 2012 Nov; 11(6):933-46. PubMed ID: 22866966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interaction with statins.
    Corsini A; Bellosta S
    Expert Rev Clin Pharmacol; 2008 Jan; 1(1):105-13. PubMed ID: 24410514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of statins: focus on clinical pharmacokinetics and drug interactions.
    Bellosta S; Paoletti R; Corsini A
    Circulation; 2004 Jun; 109(23 Suppl 1):III50-7. PubMed ID: 15198967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin drug interactions and related adverse reactions: an update.
    Bellosta S; Corsini A
    Expert Opin Drug Saf; 2018 Jan; 17(1):25-37. PubMed ID: 29058944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
    Corsini A; Ceska R
    Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Schmitz-Madry A; Ugocsai P
    Curr Opin Lipidol; 2007 Apr; 18(2):164-73. PubMed ID: 17353665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety review of combination drugs for hyperlipidemia.
    Farnier M
    Expert Opin Drug Saf; 2011 May; 10(3):363-71. PubMed ID: 21417957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of statin safety.
    McKenney JM
    Am J Manag Care; 2006 Oct; 12(11 Suppl):S310-7. PubMed ID: 17042673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin drugs: reducing cardiovascular risk in older adults.
    McLain K; Edlund BJ
    J Gerontol Nurs; 2012 Oct; 38(10):9-13. PubMed ID: 22998096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins.
    Vaquero MP; Sánchez Muniz FJ; Jiménez Redondo S; Prats Oliván P; Higueras FJ; Bastida S
    Nutr Hosp; 2010; 25(2):193-206. PubMed ID: 20449528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):745-58. PubMed ID: 22587686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin interactions with other drugs.
    Florentin M; Elisaf MS
    Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-drug interactions: not a class effect.
    Frishman WH; Horn J
    Cardiol Rev; 2008; 16(4):205-12. PubMed ID: 18562811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and myotoxicity: a therapeutic limitation.
    Tiwari A; Bansal V; Chugh A; Mookhtiar K
    Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of pharmacogenetic variation on the effects of statins.
    Maggo SD; Kennedy MA; Clark DW
    Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current overview of statin-induced myopathy.
    Rosenson RS
    Am J Med; 2004 Mar; 116(6):408-16. PubMed ID: 15006590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-induced myopathy: a review and update.
    Abd TT; Jacobson TA
    Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adverse drug reactions of hydroxymethylglutaryl-CoA reductase inhibitors reported to agency for medicinal products and medical devices].
    Skvrce NM; Bozina N; Sarinić VM; Tomić S
    Lijec Vjesn; 2010; 132(9-10):277-82. PubMed ID: 21261024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.